Genome Sequences of Two Novel Coronavirus (SARS-CoV-2) Isolates from Dhaka, Bangladesh

Matin, Mina; Sarkar, Bishajit; Ullah, Md. Asad; Araf, Yusha; Adnan, Nihad; Islam, Rizwanul; Rahman, Mohammad Shahedur

doi:10.1128/mra.00511-21

Cited by 4 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the efficacy of different types of vaccines in providing protection depends on the emerging variants of SARS-CoV-2, some of which can evade the immune system. Previously, E848K escape mutation of SARS-CoV-2 and other mutations were reported in different countries through the next-generation sequencing (NGS) method [263][264][265][266][267]. The recent concern about reinfection by the new lineage P.1 (alias of B.1.1.28.1) of SARS-CoV-2, similar to the lineage B.1.1.28, evolved in Brazil or Bengal variant in West Bengal B1.1.618, is a puzzling phenomenon for the vaccination process [268].…”

Section: Genomic Surveillance and Vaccine Up-gradationmentioning

confidence: 99%

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Khandker¹,

Godman

Jawad

et al. 2021

Vaccines

Self Cite

View full text Add to dashboard Cite

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.

show abstract

Section: Genomic Surveillance and Vaccine Up-gradationmentioning

confidence: 99%

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Khandker¹,

Godman

Jawad

et al. 2021

Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other developments in Bangladesh to improve current and future management of patients with COVID-19 include assessing antibody kinetics in these patients as well as performing genomic sequencing of different SARS-CoV-2 strains detected among COVID-19 patients [38][39][40] .…”

Section: Introductionmentioning

confidence: 99%

Pilot Study on the Current Management of Children with COVID-19 In Hospitals in Bangladesh; Findings and Implications

Nusrat

Haque

Chowdhury

et al. 2021

Bangladesh J Med Sci

Self Cite

View full text Add to dashboard Cite

Objective: The focus on COVID-19 in children in low- and middle-income countries including Bangladesh has been on addressing key issues including poor vaccination rates as well as mental health issues, domestic violence and child labour. However, the focus on optimally managing children in hospitals is changing with new variants and concerns with the development of hyperinflammatory syndromes. There are also concerns with the overuse of antimicrobials to treat patients with COVID-19 in hospitals enhancing resistance rates. The Bangladesh Paediatric Association have developed guidelines to improve patient care building on national guidance. Consequently, there is a need to document the current management of children with COVID-19 in Bangladesh and use the findings for future guidance. Methods: Rapid analysis of the management of children with COVID-19 among eight private and public hospitals in Bangladesh with varying numbers of in-patient beds using purposely developed case report forms (CRFs). The CRFs were piloted before full roll-out. Results: Overall low numbers of children in hospital with COVID-19 (4.3% of in-patient beds). The majority were male (59.6%) and aged 5 years or under (63.5%). Reasons for admission included respiratory distress/ breathing difficulties with 94.2% of COVID-19 cases confirmed. All children were prescribed antibiotics empirically, typically those on the Watch list of antibiotics and administered parenterally, with only a small minority switched to oral therapy before discharge. There was appreciable prescribing of Vitamins (C and D) and zinc and encouragingly limited prescribing of other antimicrobials (antivirals, antimalarials and antiparasitic medicines). Length of stay was typically 5 to 10 days. Conclusion: Encouraging to see low hospitalisation rates and limited use of antimicrobials apart from antibiotics. Concerns with high empiric use of antibiotics and limited switching to oral formulations can be addressed by instigating antimicrobial stewardship programmes. We will be monitoring this. Bangladesh Journal of Medical Science Vol.20(5) 2021 p.188-198

show abstract

“…The rigorous and spontaneous mutation of SARS-CoV-2 has created chaos worldwide, occurring in multiple infection waves with several deadly variants [54][55][56]. Worldwide, proper vaccine distribution and heterologous doses have become a critical concern under these circumstances [57][58][59].…”

Section: Discussionmentioning

confidence: 99%

Optimizing SARS-CoV-2 Immunoassays for Specificity in Dengue-Co-Endemic Areas

Adnan,

Haq,

Tisha

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

Introduction The overlap in clinical presentation between COVID-19 and dengue poses challenges for diagnosis in co-endemic regions. Furthermore, there have been reports of antibody cross-reactivity between SARS-CoV-2 and dengue. Our research aims to evaluate SARS-CoV-2 antigens for serological testing while reducing the possibility of cross-reactivity with anti-dengue antibodies. Method Two hundred and ten serum samples were collected from 179 patients and divided into four panels. Panels 1 and 2 consisted of COVID-19-negative healthy donors (n=81) and pre-pandemic dengue patients (n=50), respectively. Alternatively, Panel 3 (n=19) was composed of reverse transcription-quantitative polymerase chain reaction (RT-qPCR)-positive samples collected within two weeks of COVID-19 symptom onset, while Panel 4 (n=60) was composed of positive samples collected after two weeks of symptom onset. Previously developed and characterized in-house SARS-CoV-2 spike-1 (S1), receptor binding domain (RBD), and nucleocapsid (N) immunoglobin G (IgG)-enzyme-linked immunosorbent assay (ELISA) assays were used for the study. Results Six dengue-positive sera cross-reacted with the RBD of SARS-CoV-2. However, only one dengue-positive sera cross-reacted with the S1 and N proteins of SARS-CoV-2. Co-immobilization of S1 and RBD in different ratios revealed an 80:20 (S1:RBD) ratio as optimal for achieving an overall 96.2% sensitivity with the least cross-reaction to anti-dengue antibodies. Conclusion Our findings indicated that SARS-CoV-2 RBD-based immunoassays present more cross-reactivity with anti-dengue antibodies than S1 and N proteins. Furthermore, co-immobilization of S1 and RBD reduces the cross-reactivity with anti-dengue antibodies compared to RBD, thereby increasing the immunoassay specificity without affecting overall sensitivity for the dengue-endemic areas.

show abstract

Genome Sequences of Two Novel Coronavirus (SARS-CoV-2) Isolates from Dhaka, Bangladesh

Abstract: This study reports the genome sequences of two severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) strains detected in the nasopharyngeal swab specimens of two coronavirus disease-2019 (COVID-19) patients from Dhaka, Bangladesh.

Cited by 4 publications

References 11 publications

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Pilot Study on the Current Management of Children with COVID-19 In Hospitals in Bangladesh; Findings and Implications

Optimizing SARS-CoV-2 Immunoassays for Specificity in Dengue-Co-Endemic Areas

Contact Info

Product

Resources

About